JW Bioscience’s technology using tryptophanyl tRNA synthetase (WRS) as a biomarker for early diagnosis of sepsis, or blood poisoning, has been registered as a source technology from the European Patent Office.The company has secured an advantageous position in the global in-vitro diagnostic market w
Medytox said Wednesday that AbbVie has returned the rights concerning MT10109L, a botulinum toxin candidate, to the Korean company.Medytox licensed out the candidate to Allergan, which is now part of AbbVie, in 2013 and granted the exclusive right to develop and commercialize MT10109L in countries a
The Ministry of Food and Drug Safety confirmed that the risk of harm to the human body of N-nitroso-varenicline (NNV) among medicines containing varenicline, a smoking cessation treatment aid, was very low.Varenicline is the main ingredient in Pfizer's anti-nicotine therapy Champix. Thirty-four Kore
inno.N said that it would collaborate with Novacell technology to develop a peptide-based autoimmune disease treatment.Under the accord, Novacell will discover candidate substances for anti-inflammatory peptides, and inno.N plans to conduct additional research and clinical trials on the substance wi
Biopharmaceutical companies are the biggest beneficiaries of the Covid-19 outbreak, but financial reports of such companies showed that despite their hefty gains, they offered little in social contributions.Local drugmakers have significantly improved their performance due to the outbreak of Covid-1
The first and only targeted therapy to treat hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer with PIK3CA gene mutation arrived in Korea recently.However, it is uncertain whether it can get health insurance benefits.In May, Novart
Hanall Biopharma is one of the most frequently mentioned Korean drugmakers when analysts forecast the arrival of a global blockbuster drug. In developing autoimmune disease treatment candidate HL161(batoclimab), there are many ongoing clinical trials of batoclimab by partners in the U.S. and China t
Sanofi-Aventis Korea has confirmed the safety and efficacy profile of Dupixent (ingredient: dupilumab) in treating children with uncontrolled moderate-to-severe atopic dermatitis in recent studies.The company conducted phase 2/3 LIBERTY AD PRESCHOOL clinical trials with 162 patients aged six months
Locally developed drug pipelines have increased rapidly in the past three years, industry data showed.On Monday, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA) released the case study results of new drug pipelines and license transfer conducted for domestic pharmaceutical
JW Pharmaceutical’s anti-gout drug URC102 received certification from the European Patent Office (EPO) as a source technology.The patent is the company’s method to prepare a compound that works as the main ingredient and intermediate of URC102. URC102, developed as a new oral drug, inhibits uric aci
Novartis Korea has introduced its combination therapy of Piqray (ingredient: alpelisib) and fulvestrant, saying it could prolong the treatment period and overall survival (OS) of breast cancer patients with major genetic mutations.In May, the company’s breast cancer drug received approval from the M
The government decided to give reimbursement for CSL Behring’s hemophilia treatment, Abstilla, from June. SK Chemicals developed the original substance of the drug and transferred the technology to CSL Behring in 2009.The key developers of Abstilla separated from SK Chemicals and established TiumBio
Pharmanovia, a U.K.-based multinational pharmaceutical company, said that it has established a Korean branch and appointed Yim Yoon-ah as its first country manager."Founded in 2013 and headquartered in Basildon, U.K., Pharmanovia operates a portfolio of more than 20 brands with over 250 employees in
Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (ingredient: empagliflozin) received attention at the 2021 European Society of Cardiology (ESC) by unveiling the results of phase 3 EMPEROR-Preserved trial in heart failure with preserved ejection fraction (HFpEF).Sodium-Glucose Co-Transporter 2 (SGL
Korea's drug regulators have recently notified that tofacitinib, baricitinib, and upadacitinib, used for treating rheumatoid arthritis, could increase the risk of heart-related severe events.The Ministry of Food and Drug Safety (MFDS) sent out letters about the increased risk of Pfizer's Xeljanz (in
The nation’s public health insurance assessment organ has decided to provide conditional reimbursement for Xospata (ingredient: gilteritinib) in treating leukemia patients.The Health Insurance Review and Assessment Service (HIRA) reviewed whether it is appropriate to cover health insurance for Xospa
Takeda is strengthening its position in the anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) first-line treatment market with Alunbrig, armed with new data showing the drug’s superiority compared to other treatments.“If I had to choose just one, I would choose Alunbrig (I
Astellas Korea’s Xospata 40mg (gilteritinib fumarate), a treatment for acute myeloid leukemia (AML), has taken a step closer to winning health insurance benefits.On Friday, the Health Insurance Review and Assessment Service (HIRA) released the result of the drugs benefit appraisal committee’s meetin
Samyang Biopharmaceuticals' U.S. subsidiary, Samyang Biopharm USA, is pushing to develop its cancer immunotherapy drug candidate, SYB-010, through global open innovation.Samyang Biopharm USA recently signed an agreement with the Spanish National Research Council, the largest public research institut
HLB said the company would present the two interim results of combination treatment of its rivoceranib with immune-oncology and cytotoxic antineoplastic drugs at the online World Conference on Lung Cancer (WCLC) 2021 on Sept. 13.The clinical results showed a 40 percent overall response rate (ORR), 9